



Adaptive
biotechnologies™

Powering the Age of
Immune Medicine

JPM 2021 Healthcare Conference

Safe Harbor


This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to COVID-19, Lyme disease or other infectious diseases, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates, including clonoSEQ, immunoSEQ T-MAP COVID and T-Detect products, discovery and development of neutralizing antibodies and their expected efficacy with respect to SARS-CoV-2 and other disease states, planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of our anticipated product candidates; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Quarterly Report on Form 10-Q filed on November 10, 2020. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Using the immune system as the source-code for immune medicine

IMMUNE SYSTEM



GENETICS



DATA




IMMUNE MEDICINE




Research,
Diagnostics,
Drug Discovery

We translate the genetics of the immune system into clinical products


“One” Immune Medicine Platform



Synergistic Data Interplay



Immune Medicine Products




clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical summary.

T-Detect™ is an IVD for prescription use only. This test has not been cleared or approved by the FDA. The T-Detect COVID Assay is available for use as a CLIA-validated laboratory developed test (LDT). immunoSEQ® and immunoSEQ® T-MAP™ COVID are for Research Use Only. Not for use in diagnostic procedures.


Immune receptor data leads to products across multiple business areas

COVID-19




Immune receptor data leads to products across multiple business areas

CANCER



Uniquely positioned as an immune medicine product development engine

Moats Around our Platform




Speed

Scale


Precision

Broad Applications with >\$54B TAM¹



¹ Includes: ~\$1B in life science research for pharma and academic; ~\$22.3B in clinical diagnostics (~\$4.5B MRD monitoring and ~\$22.3B in accurate and early detection); ~\$31.4B in drug discovery (only includes GNE collaboration agreement for cell therapy in oncology)

Multiple opportunities for growth







**Life Science
Research**

immunoSEQ

immunoSEQ, quantifying immunology




**Repertoire
Properties**



**T-Cell
Fraction**



**Public
Clones**



Mapping

immunoSEQ


- Pioneer of immunosequencing
- Used by >2,400¹ researchers; by >165¹ biopharma partners; in >600² trials; 700 publications
- Increasing RUO Kit adoption for long term growth
 - Signed ~25 new Core Lab partnerships; CRO (Q2)

immunoSEQ T-MAP

- Mapping T-cell immune responses to specific antigens
- immunoSEQ T-MAP COVID: 1st application to measure T-cell response to SARS-CoV-2 vaccines
 - Pharma partners (AZ, Oxford/BMGF)
- immunoSEQ T-MAP Cancer: 1st pan portfolio deal (AZ) to map the immune response to cancer antigens


1 Statistics as of July 2020.

2 Statistics as of November 2019.



**Clinical
Diagnostics
clonoSEQ**

clonoSEQ, MRD monitoring gold standard in blood cancer



MRD Clinical Testing

- FDA cleared in MM, ALL (bone marrow) and CLL (bone marrow, blood)
- Reimbursed by CMS and national plans covering ~225 million lives
- Utilized in all 30 NCCN centers, >180 institutions, for >14k unique patients

MRD Pharma Trials

- Test of choice >40 biopharma companies in >190 clinical trials
- FDA drug approvals demonstrate utility of MRD
 - Venetoclax, Blinatumomab, Daratumumab
- >\$300M in potential future milestones

Unprecedented number of clonoSEQ abstracts at ASH 2020



46

ABSTRACTS
ACCEPTED



18

ORAL
PRESENTATIONS



26

PHARMA
PRESENTATIONS



28

POSTER
PRESENTATIONS



3

RWE
PRESENTATIONS

Data Highlights the Real-World Benefits

Better Outcomes

- Improved PFS following decision to change therapy based on MRD [P=0.006]

Less Invasive Testing


- Strong correlation of PB and BM MRD in ALL [r=0.87; p<0.0001]

Reduced Cost of Care

- MRD-informed discontinuation of maintenance in MM [\$181M annual savings]

clonoSEQ lifecycle plan focused on increasing access for patients

CLINICAL DIAGNOSTICS



1 Moving Into Blood

- MM: trial ongoing; data expected in 2021
- NHL: ongoing ISTs and pharma trials

2 Increasing Awareness

- Direct-to-patient campaign
- Watch Registry; our U.S prospective study

3 Expanding Team & Coverage

- U.S: adding hematology specialist team
- Ex-US: increasing tech transfer presence

*This use is not cleared or approved by the FDA and is available as part of Adaptive's CLIA-validated LDT service



**Clinical
Diagnostics
T-Detect**

T-Detect, a new category of immune-based diagnostics



Relevance of T-cells

- T-cells play a central role in the immune response to any disease, but have been difficult to study due to massive diversity
- Our TCR-antigen map makes it possible to leverage the natural diagnostic power of T-cells
 - Sensitive, specific, naturally amplified, systemic, persistent

T-Detect Indications

- T-Detect COVID: 1st indication to confirm SARS-CoV-2 recent or past infection (available as LDT)
- T-Detect Lyme: 2nd indication under development
- 3rd T-Detect signal for Crohn's disease confirmed
- Multiple diseases in the pipeline

First indication, T-Detect COVID

1st T-Cell Based Test to Confirm Past COVID Infection

Help patients get the answers they need.

Serology tests may miss patients who had COVID-19, T cells have the answer.

CONTACT US TO ORDER



Your employees want to know if they had COVID.

T cells have the answer.

CONTACT US TO ORDER



***T-Cells:
Evolved to Detect***




Go-to-Market Strategy

- Targeting self-pay consumers; concierge medicine; employers; public health agencies
- Available at T-Detect.com
 - Implementing “virtual HCP” capabilities
 - Opt-in for ongoing research about immunity
- Submitted for EUA clearance in Dec 2020
- Longer term reimbursement strategy contemplates vision of a pan disease product offering


Accelerating disease mapping through R&D pipeline

T-Detect Pipeline

- T-Detect COVID infrastructure enables acceleration of future indications
- Actively evaluating dozens of indications simultaneously to put into our 5 stage R&D funnel
- Moving diseases at a faster rate through the funnel



T-Detect Vision



¹ Development completed and available for use as a CLIA-validated laboratory developed test (LDT)




Drug Discovery

Drug discovery, identifying best-in-class TCR and BCR candidates

DRUG DISCOVERY

T-CELL THERAPEUTICS

Hundreds of antigens + Millions of TCRs



ANTIBODY THERAPEUTICS

Millions of BCRs + Virus Antigens



IND Enabling studies



TCR₁ TCR₂ ... TCR_x

BCR₁ BCR₂ ... BCR_x



IND Enabling studies


TruTCR

- Partner with GNE to characterize TCRs against cancer antigens for cellular therapy
 - Shared and private products under development
- Ability to pursue partnerships outside of oncology

TruAB

- Identified potent neutralizing antibodies against several parts of SARS-CoV-2, including outside of RBD
 - Top Abs with strong live virus neutralization
 - Low concentrations, single digit pM IC 50 live virus

Focus on 2nd shared product and scaling private product development



Potent neutralizing antibodies against COVID delivered from our platform

Current environment

- SARS-COV-2 is likely endemic in our population
- Virus mutates
- Current antibody therapies are effective but limited:
 1. Timing and method of administration
 2. Cost
 3. Unclear efficacy against new variants of the virus



Need for improved antibody therapies

Our antibodies can solve the current issues

- Search at scale identifies more potent antibodies against multiple parts of the virus, resulting in:
 - Potential use at low concentration that may enable simpler administration at lower cost
 - Potential to avoid mutations

NAb clone	Spike Region	Binding EC ₅₀ (pM)	Live Virus Neutralization Average IC ₅₀ (pM)
ADPT02050	RBD	25	3 (0.5 - 16)
ADPT00980	RBD	23	8 (5 - 13)
ADPT02020	RBD	88	9 (5 - 23)
ADPT02793	S1 (non-RBD)	Pending	11 (0 - 30)
ADPT02019	Trimer (non-RBD)	24	33 (19 - 56)
Control	RBD	150 ± 30	827 (480 - 1380)

IC50s are averages estimated from replicates and up to 3 different experiments. Range shows estimated 95% confidence interval.

2021 Catalysts

Life Science Research

- Embed T-MAP COVID into SARS-CoV-2 vaccine trials
- Expand immunoSEQ T-MAP data offering into other disease categories
- Expand distribution of immunoSEQ RUO kit

Clinical Diagnostics

- FDA clearance for clonoSEQ ALL in blood
- T-Detect COVID EUA clearance; commercialization
- ImmuneSENSE study completion and T-Detect Lyme launch
- Confirm additional T-Detect signal(s)

Drug Discovery

- GNE expected to file IND for first shared product in Q1 2021
- Private product proof of concept data expected Q1 2021
- Complete 2nd share product data package for GNE
- Pursue neutralizing antibody pathway


If you believe in Immune Medicine, believe in Adaptive

- ✓ **Differentiated vision**
- ✓ **Unparalleled science & data**
- ✓ **Strong execution record**
- ✓ **Diverse & experienced team**
- ✓ **Well capitalized**



Thank You.

Appendix: Clinical portfolio and pipeline



* Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The "1st Shared" and "2nd Shared" product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to the FDA.

** Product candidates in development.